Please use this identifier to cite or link to this item:
Title: NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Austin Authors: Jack, Clifford R;Bennett, David A;Blennow, Kaj;Carrillo, Maria C;Dunn, Billy;Haeberlein, Samantha Budd;Holtzman, David M;Jagust, William;Jessen, Frank;Karlawish, Jason;Liu, Enchi;Molinuevo, Jose Luis;Montine, Thomas;Phelps, Creighton;Rankin, Katherine P;Rowe, Christopher C ;Scheltens, Philip;Siemers, Eric;Snyder, Heather M;Sperling, Reisa
Affiliation: Department of Public Health and Neuroscience, University of California Berkeley, Berkeley, CA, USA
Department of Radiology, Mayo Clinic, Rochester, MN, USA
Department of Neurological Sciences, Rush University, Chicago, IL, USA
Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA
Office of Drug Evaluation, FDA, Silver Spring, MD, USA
Biogen, Cambridge, MA, USA
Department of Neurology, Washington University, St. Louis, MO, USA
Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany
Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Prothena Biosciences, Inc., San Francisco, CA, USA
BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain
Department of Pathology, Stanford University, Standford, CA, USA
Formerly at National Institute on Aging, Bethesda, MD, USA
Department of Neurology, University of California San Francisco, San Francisco, CA, USA
Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
Formerly at Eli Lilly and Company, Indianapolis, IN, USA
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Apr-2018
Publication information: Alzheimer's & dementia : the journal of the Alzheimer's Association 2018; 14(4): 535-562
Abstract: In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker-based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.
DOI: 10.1016/j.jalz.2018.02.018
ORCID: 0000-0003-3910-2453
PubMed URL: 29653606
Type: Journal Article
Subjects: Alzheimer's disease diagnosis
Alzheimer's disease imaging
Amyloid PET
Biomarkers Alzheimer's disease
CSF biomarkers Alzheimer's disease
Preclinical Alzheimer's disease
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 6, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.